Teleflex Receives FDA Clearance for 150 cm Length Arrow GPSCath Balloon Dilatation Catheters
PTA balloon catheters combine angioplasty with targeted injection system in a single device for use in below-the-knee procedures.
WAYNE, Pa. — July 29, 2014 — Teleflex Incorporated, a global provider of medical devices for critical care and surgery, has announced that its subsidiary Hotspur Technologies, Inc. received FDA 510(k) clearance to market the Arrow GPSCath Balloon Dilatation Catheters designed for use with .014" guide wires and in 150 cm length. These products enable a variety of peripheral vascular procedures to be performed below the knee with one dual-function catheter, potentially reducing procedure time, radiation dosage, and expense for both patients and medical professionals.
The Arrow GPSCath Balloon Dilatation Catheter is the first dual functional balloon dilatation catheter that combines angioplasty with the proprietary VisioValve Injection System. This combination enables physicians to perform peripheral below-the-knee angioplasty and inject physician-selected fluids, such as contrast media, while maintaining guide wire position.
About Teleflex Incorporated
Headquartered in Wayne, PA, Teleflex employs approximately 11,400 people worldwide and serves healthcare providers in more than 150 countries. Additional information about Teleflex can be obtained from the company's website at teleflex.com.